NPS Pharmaceuticals Appoints Dr. Alan G. Harris Chief Medical Officer
NPS Pharmaceuticals, Inc. announced the appointment of Alan G. Harris, M.D., Ph.D., as senior vice president and chief medical officer.
Before joining NPS, Dr. Harris was chief medical officer of Manhattan Pharmaceuticals, therapeutic head of worldwide medical endocrine care at Pfizer, Inc., and vice president of global health research and outcomes at Schering-Plough Corp. where he held a variety of senior medical affairs positions. While at Sandoz (now Novartis), Dr. Harris developed, as project leader, the first long-acting somatostatin analogue, octreotide (Sandostatin (R)), for the treatment of gastrointestinal tumors and endocrine diseases.
Dr. Harris currently holds several academic appointments, including adjunct professor in the department of pharmacology at NYU Medical Center in New York, and was previously associate professor of medicine at UCLA Medical School and director of the division of clinical pharmacology in the department of medicine at Cedars-Sinai Medical Center. He has authored over 100 peer-reviewed scientific articles. Dr. Harris is a fellow of the American College of Physicians and a fellow of the Royal College of Physicians (UK).
Dr. Harris received his doctor of medicine degree from the University of Strasbourg, France and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. He undertook post-graduate training in hepatogastroenterology and nutrition from Nice University Medical School, France.
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
